Park Wan Beom, Hwang Young Hoon, Kwon Ki Tae, Noh Ji Yun, Park Sun Hee, Song Joon Young, Choo Eun Ju, Choi Min Joo, Choi Jun Yong, Heo Jung Yeon, Choi Won Suk
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Division of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
Infect Chemother. 2024 Dec;56(4):453-460. doi: 10.3947/ic.2024.0142.
The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024-2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.
自2007年以来,韩国传染病协会定期发布成人免疫指南。2023年发布2019冠状病毒病(COVID-19)疫苗接种建议后,由于新变异毒株的出现以及先前接种疫苗后免疫力的下降,情况发生了重大变化。本文提供截至2024年11月的全面更新内容,纳入了最新证据和指南。本文聚焦2024 - 2025年季节,回顾了韩国目前批准使用的疫苗,并评估了它们对主要的JN.1谱系变异毒株的有效性。更新后的建议将65岁及以上成年人、有基础疾病的个体、易受感染机构的居民、孕妇和医护人员等高风险人群列为优先接种针对JN.1毒株的更新疫苗的对象。此外,6个月及以上的所有人均可接种COVID-19疫苗。对于大多数成年人,强调采用单剂接种策略,而对于免疫功能低下的个体,可能会推荐量身定制的接种时间表。此次更新旨在优化韩国的疫苗接种策略,以确保为高风险人群提供全面保护。